Sculptor Capital’s GoodRx Holdings GDRX Stock Holding History

Sculptor Capital’s Portfolio GDRX Stock Details GDRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-159,200	Closed	-$5.2M	–	1256
2021 Q4	$5.2M	Hold	159,200	–	–	0.04%	353
2021 Q3	$6.53M	Hold	159,200	–	–	0.05%	250
2021 Q2	$5.73M	Buy	+159,200	New	+$5.88M	0.04%	279

Other funds holding GDRX

FPM

Francisco Partners Management San Francisco, California $292M AUM 34.13% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

LSCM

Light Street Capital Management Palo Alto, California $534M AUM 59.08% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

SLG

Silver Lake Group Menlo Park, California $3.68B AUM 7.22% 1-Year Est. Return

TCMX

Technology Crossover Management X Menlo Park, California $781M AUM 18.39% 1-Year Est. Return

DIG

Dragoneer Investment Group San Francisco, California $3B AUM 6.95% 1-Year Est. Return

RRCP

Rip Road Capital Partners Boston, Massachusetts $62.5M AUM 1.22% 1-Year Est. Return

LOAMS

Lombard Odier Asset Management (Switzerland) Petit-Lancy, Switzerland $2.63B AUM 31.52% 1-Year Est. Return

Sculptor Capital's GDRX Position: Q1 2022 in Review

Sculptor Capital sold out of GoodRx Holdings (GDRX) in Q1 2022, closing a stake of 159,200 shares — an estimated $5.2M sold.

Sculptor Capital first reported a position in GDRX in Q2 2021 and held it in 3 quarters. The position peaked at $6.53M in Q3 2021. 167 funds tracked by Wall St. Rank hold GDRX as of Q1 2022.

Sculptor Capital reported no remaining GoodRx Holdings position as of Q1 2022 after selling out during the quarter.
Sculptor Capital sold 159,200 GoodRx Holdings shares in Q1 2022, an estimated $5.2M.
Sculptor Capital first reported a position in GoodRx Holdings in Q2 2021 and held it in 3 quarters.
Sculptor Capital's GoodRx Holdings position peaked at $6.53M in Q3 2021.
167 funds tracked by Wall St. Rank held GoodRx Holdings as of Q1 2022.

Based on Sculptor Capital's 13F filing for Q1 2022, filed 13 May 2022.